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Abstract
New diagnostics and vaccines for tuberculosis (TB) are urgently needed, but require an understanding of the requirements for
protection from/susceptibility to TB. Previous studies have used unbiased approaches to determine gene signatures in single-site
populations. The present study utilized a targeted approach, reverse transcriptase multiplex ligation-dependent probe ampliﬁcation
(RT-MLPA), to validate these genes in a multisite study. We analysed ex vivo whole blood RNA from a total of 523 participants across
four sub-Saharan countries (Ethiopia, Malawi, South Africa, and The Gambia) with differences in TB and human immunodeﬁciency virus
(HIV) status. We found a number of genes that were expressed at signiﬁcantly lower levels in participants with active disease than in
those with latent TB infection (LTBI), with restoration following successful TB treatment. The most consistent classiﬁer of active disease
was FCGR1A (high-afﬁnity IgG Fc receptor 1 (CD64)), which was the only marker expressed at signiﬁcantly higher levels in participants
with active TB than in those with LTBI before treatment regardless of HIV status or genetic background. This is the ﬁrst study to
identify a biomarker for TB that is not affected by HIV status or geo-genetic differences. These data provide valuable clues for
understanding TB pathogenesis, and also provide a proof-of-concept for the use of RT-MLPA in rapid and inexpensive validation of
unbiased gene expression ﬁndings.
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Introduction
Tuberculosis (TB) is a global health problem, with c. 2 billion
people infected worldwide. Of these, 3–10% will progress to
active TB disease, resulting in almost 9 million cases and
1.5 million deaths per year [1]. Infection with human immu-
nodeﬁciency virus (HIV) is the most potent known risk factor
for progression to TB: patients with HIV are more likely to
progress directly to active disease or reactivate latent TB
infection (LTBI) than immunocompetent individuals [1,2].
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The outcome of the immune response to TB is determined
by the host immune status, host genetics, and the virulence of
the pathogen, Mycobacterium tuberculosis. For instance, changes
in mycobacterial gene expression are seen in different stages of
TB infection, resulting in poor generation of immunological
memory. Additionally, distinct lineages of M. tuberculosis are
present in different geographical locations [3], contributing to
differential immune responses, owing to variations in virulence
[3]. It therefore remains difﬁcult to determine the require-
ments for a protective immune response to TB. Comparison
of the immune response between individuals with different
stages of TB infection and disease may enable speciﬁc immune
responses to be targeted for improved diagnostics and
treatment outcome, and the determination of surrogate
markers for vaccine efﬁcacy studies [4,5].
A number of changes in the innate and adaptive arms of the
immune system have been described with active TB disease,
including monocytes [6], neutrophils [7], CD4+ and CD8+
T-cells [8–11], polyfunctional cytokine proﬁles [12,13], and
secretion products following antigenic stimulation [14,15].
Unbiased gene expression proﬁling, such as with microarrays,
can provide insights into biomarkers and networks that may
provide new targets for diagnostic and vaccine development.
These techniques have elucidated gene expression proﬁles that
showmarked differences between active TB and LTBI, including
type I and II interferon signalling pathways [16,17], innate cell
pathways [18], the Fcc receptor 1 network [19,20], andmarkers
of apoptosis [19].
These promising data stem from relatively small studies in
speciﬁc geographical areas and in immunocompetent hosts.
Thus, validation of these results in large, diverse populations is
critical. A novel dual-colour reverse transcriptase multiplex
ligation-dependent probe ampliﬁcation (RT-MLPA) assay was
recently described that can monitor the expression of a
restricted set of genes on a population scale in a fast and
inexpensive fashion [21]. The present study extended this line
of investigation across four African countries, using a large
cohort of 523 participants (both HIV-positive and HIV-nega-
tive), and provides a proof-of-concept for the use of the assay
in the validation of potential gene targets determined with
unbiased approaches. Importantly, we found expression of
FCGR1A to be signiﬁcantly higher in participants with active TB
than in those with LTBI, regardless of HIV status or ethnicity.
Methods
Participants and study sites
The study design for Grand Challenges in Global Health
(GC6-74) has been previously described [4]. Sites included:
The Gambia (Medical Research Council Unit); Ethiopia
(Ethiopian Health and Nutrition Research Institute (EHNRI));
Malawi (Karonga Prevention Study (KPS)); and South Africa
(Stellenbosch University (SUN)). Participants were considered
for inclusion if they were >18 years of age, had no concurrent
infections, and were willing to undergo an HIV test. All
HIV-positive participants were antiretroviral therapy-na€ıve
prior to recruitment. Participants without TB were recruited
from households of TB patients (Medical Research Council
Unit and SUN) or by random community selection and from
HIV care clinics (KPS and EHNRI) (household or community
controls). All participants underwent a clinical assessment,
including a screen for malaria (except for SUN) and
concurrent illness and chest X-ray. Tuberculin skin tests
(TSTs) (two tuberculin units; PPD RT23, SSI, Copenhagen,
Denmark) were performed in order to further classify the
HIV-negative participants without active disease as TST-po-
sitive or TST-negative. TB cases were conﬁrmed by sputum
culture (BACTEC; Becton-Dickinson, San Jose, CA, USA). If
BACTEC was not available, culture on Lowenstein–Jensen
solid medium was performed (KPS and EHNRI). After written
informed consent had been obtained, venous blood was
collected into PAXgene RNA tubes (Qiagen, Hilden, Ger-
many) for subsequent RNA isolation. Ethical approval was
obtained from local ethics committees, and also from the
London School of Hygiene and Tropical Medicine for Malawi
participants. Participant information is shown in Table S1.
RT-MLPA
RNA was isolated from PAXgene tubes with extraction kits
according to the manufacturer’s instructions (Qiagen).
RT-MLPA was performed as previously described [22,23],
with several major modiﬁcations [21]. Brieﬂy, 100–150 ng of
RNA was reverse transcribed with gene-speciﬁc reverse
transcription primers and Moloney murine leukaemia virus
reverse transcriptase. This was denatured and hybridized
overnight at 60°C with a gene-speciﬁc probe mix in SALSA
buffer (MRC Holland, Amsterdam, The Netherlands). After
treatment of the samples with ligase-65 (MRC Holland) for
15 min at 54°C, PCR ampliﬁcation was performed with
speciﬁc SALSA FAM-labelled or HEX-labelled multiplex
ampliﬁable probe hybridization primers (2 lM each; forward
primer, 5′-GGCCGCGGGAATTCGATT-3′; reverse primer
5′-GCCGCGAATTCACTAGTG-3′), 13.75 lL of H2O, and
0.25 lL of SALSA polymerase [21]. PCR conditions were 33
cycles of 30 s at 95°C, 30 s at 58°C, and 60 s at 72°C,
followed by one cycle of 20 min at 72°C. PCR products were
then diluted 1 : 10 in HiDi formamide containing 400 HD
ROX size standards, and analysed on an ABI PRISM 3730
capillary sequencer (Applied Biosystems, Warrington, UK).
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Data were analysed with GeneMapper software (Applied
Biosystems). Peak areas were exported to a Microsoft Excel
ﬁle, and normalized by adjustment to the glyceralde-
hyde-3-phosphate dehydrogenase housekeeping gene. Signals
below the threshold value for noise cut-off (peak area ≤ 200)
were adjusted accordingly. A positive control that encom-
passed the combined gene-speciﬁc sequences of the left-hand
and right-hand half-probes was used for all runs. Detailed
descriptions of the genes analysed are given in Table S2.
Statistical analysis
The Mann–Whitney U-test was used for analysis of participants
within each site. For HIV-positive participants, analysis of CD4
counts within and between sites was performed with a
Kruskal–Wallis test and Dunn’s post-test comparison. Because
of differences between sites with regard to CD4 counts,
HIV-positive participants were analysed both with unadjusted
and with adjusted CD4 counts by the use of linear regression.
A Kruskal–Wallis test followed by Dunn’s post-test compar-
ison was used to determine differences between TB cases and
TST-positive and TST-negative contacts. Logistic regression
and receiver operator curve analyses were used to determine
which parameters best discriminated between TB cases and
controls. Analyses were performed with Graphpad Prism 6
(Software MacKiev, Valley Stream, NY, USA) and SPSSv20
(IBM, Armonk, NY, USA), and adjusted for age and sex.
Signiﬁcance was deﬁned as a p-value of ≤ 0.035 to adjust for
false-discovery rates with multiple-comparison testing.
Results
Analysis of gene expression relative to TB and HIV status
Gene expression levels were analysed for individual sites, and
also collated for analysis of total HIV-negative and HIV-positive
participants. Some genes showed baseline expression in all
participants, and were excluded from the ﬁnal analyses. These
were generally cytokine-related genes, including IL4, IL4D, IFNG,
TNFA, and IL2. Detailed descriptions of the ﬁnal 33 genes
analysed are given in Table S2. Many genes were expressed at
low levels (Figs 1 and 2), including CXCL10 and the lactotrans-
ferrin gene (LTF), but their expression tended to be higher in
Gambian participants than in South African or Malawian
HIV-negative participants. For HIV-positive participants, low
Gene
SUN
TB+
SUN
TB– p-value
KPS 
TB+
KPS 
TB– p-value
MRC
TB+
MRC
TB– p-value
CD8A 1729 2624 0.0022 3721 7780 0.0061 1494 1515 ns
CXCL10 200 200 ns 200 200 ns 249 217 ns
CD4 5742 6933 ns 4765 6918 <0.0001 4623 5680 0.0004
BLR1 1340 3218 <0.0001 200 200 0.0002 911 1774 <0.0001
SEC14L1 15191 21633 0.0023 11112 17952 <0.0001 19224 19931 ns
TIMP2 20583 23673 ns 18239 19358 ns 18340 16476 ns
CCL19 200 200 ns 200 200 ns 566.5 532 ns
FPR1 17627 13547 ns 9553 8536 ns 22881 17075 ns
NCAM1 200 200 ns 200 200 ns 985.5 1087 ns
FOXP3 200 1808 ns 2290 200 ns 2598 3428 ns
TGFBR2 4127 5622 0.0049 3087 4743 <0.001 5400 6085 ns
IL7R 12932 25678 <0.0001 6897 24426 <0.0001 10695 17518 <0.0001
BCL2 3905 6560 <0.0001 2230 5196 <0.0001 2011 2961 0.0032
CASP8 19164 22508 0.0088 13124 17343 <0.0001 11675 13217 ns
BPI 200 200 ns 200 200 ns 1134 948 ns
CCR7 3483 6494 <0.0001 11091 200 <0.0001 13922 16220 ns
CCL22 200 200 ns 200 200 ns 477 400 ns
MMP9 1477 200 ns 200 200 ns 859 414 ns
RAB24 200 200 ns 2022 200 ns 3238 3088 ns
LTF 200 200 ns 200 200 ns 404 200 0.0008
CD163 200 200 ns 200 200 ns 1003 1168 ns
TGFB1 3599 4197 0.0153 5486 6733 <0.0001 7017 7261 ns
TNFRSF1B 200 200 ns 2184 3039 ns 4116 4434 ns
FCGR1A 4880 200 <0.0001 3551 200 <0.0001 2501 947 <0.0001
TNFRSF1A 22275 22756 ns 18264 17239 ns 15798 15195 ns
RAB13 200 200 ns 200 200 ns 527 1063 0.0004
CD3E 15550 31909 <0.0001 13052 31409 <0.0001 13552 20815 <0.0001
Low High
FIG. 1. Differential gene expression values in human immunodeficiency virus (HIV)-negative participants from South Africa (SUN), Stellenbosch
University; Malawi (KPS), Karonga Prevention Study; The Gambia (MRC), Medical Research Council Unit. RT-MLPA was performed on ex vivo RNA
extracted from tuberculosis cases (TB+) and household or community controls (TB–). Median values are shown. Blue indicates relatively low
expression and red indicates relatively high expression. Data were analysed with Mann–Whitney U-test for each site; p-values are indicated; NS, not
significant.
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expression of CD163, CCL19 and RAB13was seen at all sites, for
all participants (Fig. 2). High expression of SEC14L1, FPR1,
TGFBR2 and TNFRSF1A was seen for HIV-negative participants
at all sites, regardless of TB status (Fig. 2). For HIV-positive
participants, all sites showed high expression of SEC14L1,
TIMP2, CD3E, and TNFRSF1A (Fig. 2). There were also some
notable differences between sites, with participants from
Malawi and South Africa, but not from The Gambia, showing
signiﬁcantly different expression of several genes in HIV-neg-
ative TB cases and vice versa. These included CD8, SEC14L1,
TGFB1, TGFBR2, and CASP8; all had signiﬁcantly lower expres-
sion in participants with active TB than in contacts from South
Africa and Malawi, but no difference was seen between the
groups in The Gambia (Fig. 1). Interestingly, median CCR7
expression levels were signiﬁcantly lower in TB cases (3483)
than in contacts (6494) from South Africa, but were signiﬁ-
cantly higher in cases (11091) than in contacts (200) from
Malawi (again, the difference was not signiﬁcant for The
Gambia; Fig. 1). Conversely, LTF expression was signiﬁcantly
higher and RAB13 expression was signiﬁcantly lower in cases
than in contacts in The Gambia, but no differences were seen
for either in South Africa or Malawi (Fig. 1).
Differential BLR1, FCGR1A, CD3E and IL7R expression levels
were seen between TB cases and controls, regardless of HIV
status (Fig. 2 (all sites) and Fig. 3). There were also some genes
that only showed differences in HIV-negative participants,
including apoptotic marker genes (BCL2 and CASP8), CD4,
regulatory T-cell marker genes (FOXP3, TGFB1, and TGFBR2)
and intracellular trafﬁcking marker genes (RAB13, RAB24, and
SEC14L1). Similarly, some differences were only associated
with HIV-positive participants, including the chemokine
marker genes CXCL10 and CCL22, and the innate immunity
marker genes LTF and MMP9 (Fig. 2). Owing to signiﬁcant
differences between sites with regard to CD4 counts at the
time of recruitment of HIV-positive participants, we adjusted
for CD4 counts by using linear regression, and found the
expression of all genes to be signiﬁcantly different between
FIG. 2. Differential gene expression values in human immunodeficiency virus (HIV)-positive participants per site and total HIV-negative and HIV-
positive participants (all sites grouped). RT-MLPA was performed on ex vivo RNA extracted from tuberculosis cases (TB+) and household or
community controls (TB). Median values are shown. Blue indicates relatively low expression and red indicates relatively high expression. Data
were analysed with Mann–Whitney U-test for each site and for total HIV-negative and HIV-positive participants (all sites combined); p-values are
indicated; EHNRI, Ethiopian Health and Nutrition Research Institute; SUN, Stellenbosch University; KPS, Karonga Prevention Study; NS, not
significant.1
1Figure 2 was updated on 13/01/2014, after ﬁrst online publication 11/11/2013.
The values in the EHNRI TB+ and TB are now correct; previously the values in
the TB+ column appeared in the TB column and vice versa.
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HIV-positive cases and controls, both with site-
speciﬁc analysis and with grouped analysis (data not shown).
The only marker whose expression was consistently higher in
active disease than in controls was FCGR1A, which was
signiﬁcantly different regardless of HIV status or site, even
with unadjusted CD4 counts (Figs 1–3).
Gene expression differences between participants with active
TB disease, participants with LTBI (TST-positive), and
non-infected (TST-negative) healthy controls
When TST-positive (LTBI) and TST-negative healthy controls
were separated and compared with participants with active
disease (data available only for HIV-negative participants), a
similar pattern emerged (Table 1). TB cases had signiﬁcantly
lower expression of BCL2, CASP8, CXCR5, CD3, CD4, CD8, IL7R,
TGFB1, TNFRSF1B, TGFBR2 and SEC14L1 but signiﬁcantly higher
expression of FCGR1A than participantswith LTBI (TST-positive)
(Table 1). Participants with LTBI had signiﬁcantly higher
expression of BCL2 and CASP8 than TST-negative participants.
However, expression levels ofCCL22, CD163,NCAM1 andCD19
were all signiﬁcantly lower in TST-positive participants than in
TST-negative contacts (Table 1). The majority of markers had
signiﬁcantly lower expression in TB cases than in TST-positive
participants, except for FCGR1A, which had a median expression
level of 4200 in TB cases as compared with 200 in TST-positive
and TST-negative contacts (p <0.001; Table 1). The expression
levels of all markers were restored to LTBI levels following
successful TB treatment (data not shown).
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FIG. 3. Reverse transcriptase multiplex
ligation-dependent probe ampliﬁcation
was performed on ex vivo RNA
extracted from tuberculosis cases (TB+)
and household or community controls
(TB) at four sites in Africa. Data are
presented from a total of 141 human
immunodeﬁciency virus (HIV)-negative
TB-positive, 195 HIV-negative
TB-positive, 74 HIV-positive TB-positive
and 120 HIV-positive TB-negative
participants. Line indicates median,
whiskers indicate 5–95% range, and dots
indicate outliers. Data were analysed with
the Kruskal–Wallis test followed by
Dunn’s post-test comparison.
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Classiﬁcation of active TB
We performed receiver operator curve analysis to determine
which marker resulted in the best speciﬁcity and sensitivity
for classiﬁcation of active TB. For HIV-positive participants,
the best classiﬁer was FCG1RA (area under the curve
(AUC) = 0.75), followed by CXCL10 (AUC = 0.73) and
CD3E (AUC = 0.70), and this did not change when we
adjusted for CD4 counts (Fig. 4, left panel); however,
controls were a mixture of TST-positive and TST-negative.
For HIV-negative participants, classiﬁcation into active TB
disease or LTBI (only TST-positive participants) was much
better: CD3E correctly classiﬁed 89% of participants
(AUC = 0.89), followed by IL7R (AUC = 0.88) and FCGR1A
(AUC = 0.87) (Fig. 4, right panel). Multiple logistic regression
analysis revealed that a combination of FCGR1A, BCL2 and
IL7R could correctly classify 91% of HIV-negative participants
into active TB disease or LTBI. The success rate was much
lower for HIV-positive participants, with FCGR1A, CD3 and
CXCL10 resulting in a 75% classiﬁcation of TB with all sites
combined, with or without adjustment for CD4 counts.
Discussion
The ability to determine natural protective immunity to TB
requires multisite studies, owing to the relatively low rate of
progression from latent infection to active TB, and the
inﬂuence of HIV co-infection and genetics on the outcome of
the immune response. The Bill & Melinda Gates Foundation
Grand Challenge 6 was designed with this in mind: it was a
large, multisite project that incorporated all infectious states of
TB (TST-negative, TST-positive and active disease, pretreat-
ment and post-treatment) in HIV-positive and HIV-negative
participants from seven sites in Africa (four included in this
study), providing a unique opportunity to identify biomarkers
for protection against TB that could be targeted for vaccine
efﬁcacy, diagnostics and treatment outcome studies.
In this study, we used RT-MLPA to analyse ex vivo whole
blood RNA with a speciﬁc set of gene targets that are known to
be involved in or affected by TB pathogenesis. We show that
this approach is feasible for identifying differential gene
expression across different geographical sites, across HIV and
TB infection phenotypes, and in larger participant groups than
are currently practicable, through unbiased transcriptomic
analysis. This is important, because the majority of previous
studies have been based on HIV-negative participants from one
site only.
There were a number of genes in HIV-negative participants
that showed distinct differences between the index cases and
their household contacts regardless of the study site (and
therefore underlying genetic make-up), particularly genes
encoding T-cell markers (CD3 and IL7R), BCL2 (apoptotic
regulator), CXCR5 (chemokine), FCGR1A (CD64) (high-afﬁnity
IgG receptor), and SEC14L (Golgi marker). There were also
some notable differences between sites, with participants
from Malawi and South Africa showing signiﬁcant reductions
in expression levels of genes in TB cases that were not
observed in The Gambia and vice versa. For instance, the
expression of CD8, which encodes the characteristic marker
of the T-cell population with cytolytic functions, was signif-
icantly lower in TB cases from South Africa and Malawi but
not The Gambia, whereas RAB13 and LTF expression levels
TABLE 1. Analysis of gene expression variation with different tuberculosis infection and disease states for human immunode-
ﬁciency virus-negative participants (median (interquartile range) 3 102)
TB TST+ HHC TST HHC TB vs. TST TB vs. TST+ TST vs. TST+
Gene n = 99 n = 91 n = 49 p-value p-value p-value
BCL2 29 (19–42) 5 (30–71) 33 (26–46) NS <0.001 <0.01
CASP8 145 (106–186) 180 (141–224) 145 (120–179) NS <0.001 <0.01
TNFRSF1B 22 (2–39) 31 (2–39) 36 (30–48) <0.001 NS NS
CXCR5 2 (2–15) 24 (12–41) 19 (2–27) <0.001 <0.001 NS
CCL22 2 (2–2) 2 (2–2) 2 (2–5) NS NS <0.01
CD163 2 (2–11) 2 (2–10) 9 (2–14) NS NS <0.01
NCAM1 2 (2–8) 2 (2–9) 9 (2–17) <0.001 NS <0.01
CD19 2 (2–2) 2 (2–5) 6 (2–11) <0.001 NS <0.001
FCGR1A 42 (23–61) 2 (2–13) 2 (2–7) <0.001 <0.001 NS
CD3 140 (105–197) 294 (220–351) 249 (190–308) <0.001 <0.001 NS
CD4 53 (31–67) 65 (52–83) 65 (53–81) <0.01 <0.001 NS
CD8A 18 (2–36) 26 (13–74) 19 (2–41) NS <0.01 NS
IL7R 102 (62–139) 227 (172–278) 191 (143–256) <0.001 <0.001 NS
FOXP3 21 (2–26) 26 (2–43) 3 (2–26) NS NS NS
TGFB1 49 (40–60) 64 (45–73) 65 (56–74) <0.001 <0.001 NS
TGFBR2 39 (21–54) 55 (44–65) 54 (45–64) <0.001 <0.001 NS
RAB13 2 (2–2) 2 (2–7) 7 (2–12) <0.001 NS NS
SEC14L1 147 (109–207) 197 (154–244) 212 (156–239) <0.001 <0.001 NS
NS, not signiﬁcant; TB, participants with active tuberculosis disease; TST+ HHC, tuberculin skin test-positive household contacts; TST HHC, tuberculin skin test-negative
household contacts.
Data are shown for the most differentially expressed genes.
Data were analysed with a Kruskal–Wallis test followed by Dunn’s post-test comparison.
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were different between cases and controls in The Gambia but
not in South Africa or Malawi. LTF regulates immune
responses to a number of infections by modulating functions
of antigen-presenting cells [24], and has recently been shown
to boost bacille Calmette–Guerin vaccine responses when
used as an adjuvant [25]. The differences between sites may
be attributable to the selection criteria for the control group,
but is more probably attributable to underlying genetics, as
participants from The Gambia appeared to diverge more than
participants from South Africa and Malawi. Pathogen strain
and lineage differences may also be relevant, particularly as
Mycobacterium africanum, which appears to be less virulent
than M. tuberculosis [26], is prevalent only in West Africa.
Fewer genes showed consistent results across sites in
HIV-positive participants, with CD14, FCGR1A and CD8A being
the three main markers that differed between TB cases and
controls for all sites. When results were combined from all
sites, 14 genes showed a difference between cases and
controls in HIV-negative participants and ten in HIV-positive
participants. These were quite distinct, with HIV-negative
participants being more likely to show differences in secretory
genes and regulatory T-cell genes (i.e. FOXP3 and CTLA4), and
HIV-positive participants showing most differences in chemo-
kine markers and innate immune markers. Four genes showed
signiﬁcant differences in both HIV-negative and HIV-positive
(all sites combined) participants, including BLR1, IL7R, FCGR1A,
and CD3E. Importantly, when TB cases vs. TST-positive HHCs
(LTBI) were analysed, a similar pattern of markers emerged,
with the addition of CASP8 (apoptotic regulator), CD4, CD8,
TGFB1, and SEC14L1.
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FIG. 4. Reverse transcriptase multiplex ligation-dependent probe ampliﬁcation was performed on ex vivo RNA extracted from tuberculosis (TB)
cases and tuberculin skin test (TST)-positive household or community controls (HCCs) from four sites in Africa. Data are presented from a total of
99 TB cases and 91 TST-positive HHCs (all human immunodeﬁciency virus (HIV)-negative). Data were analysed by the use of using receiver operator
curves, and sensitivity and speciﬁcity are shown for IL7R, FCGR1A, and CD3E. AUC, area under the curve.
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Interestingly, whereas the majority of markers had signif-
icantly lower expression in TB cases than in controls, FCGR1A
was the only marker whose expression was consistently and
signiﬁcantly increased in TB cases, regardless of HIV status,
showing that identiﬁcation of universal biomarkers is achiev-
able. KEGG pathway analysis has revealed that FCGR1A is
functionally associated with immunoregulatory genes, partic-
ularly with apoptotic regulators and proinﬂammatory regula-
tors involved in the JAK–STAT pathway [20]. Our data are in
line with previous ﬁndings in South African participants,
showing a signiﬁcant reduction in FCGR1A expression following
treatment for TB [27]. FCGR1A is mainly expressed by
monocytes and macrophages, is induced by interferon-c, and
plays a central role in antibody-dependent cytotoxicity and the
clearance of immune complexes. It also helps to control Mtb
via stimulation of the respiratory burst in intracellular
mononuclear phagocytes [28]. These ﬁndings require further
validation, but our results indicate the likely importance of
FCGR1A in TB pathogenesis regardless of the immune status of
the host.
In conclusion, the ﬁndings from this study incorporated
within the GC6-74 consortium have provided valuable
clues for understanding TB pathogenesis, and also provides a
proof-of-concept for the use of RT-MLPA in rapid and inexpen-
sive validation of unbiased gene expression ﬁndings.
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